Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
DURHAM, N.C., and BEIJING, China – June 9, 2021
DURHAM, N.C., and BEIJING, China – June 9, 2021 – Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced that it will present the complete dataset from its Phase 1b/2a study evaluating Brii-179 (VBI-2601) as a treatment for chronic hepatitis B virus (HBV) infection as a late-breaker ePoster at the European Association for the Study of the Liver’s (EASL) International Liver Congress 2021, which is taking place virtually from June 23-26, 2021.
BRII-179 (VBI-2601) is a novel recombinant, protein-based immunotherapeutic candidate, which is being developed and led by Brii in partnership with VBI Vaccines (“VBI”) for patients with chronic hepatitis B virus (HBV) infection. Brii entered into a license and collaboration agreement with VBI in December of 2018, and VBI previously announced positive interim data from this Phase 1b/2a study in November of 2020 and April of 2021.
The ePoster will be available to view via the conference site on Wednesday, June 23, 2021 at 8:00am CET/2:00am ET. Additional details of the late-breaker ePoster presentation are as follows:
Abstract Number: PO-2575
Presentation Title: Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study
Presenter: Man-Fung Yuen, DSc, MD, PhD, Professor of Medicine at the Li Shu Fan Medical Foundation, Chief of Gastroenterology and Hepatology and Deputy Head of the Department of Medicine at The University of Hong Kong, Deputy Chief of Service of the Department of Medicine at Queen Mary Hospital, Hong Kong and the Assistant Dean of the Faculty of Medicine at the University of Hong Kong
About Hepatitis B
Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 780,000 people die each year from complications of chronic HBV such as liver decompensation and hepatocellular carcinoma.
About BRII-179 (VBI-2601)
BRII-179 (VBI-2601) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate, and is designed to target enhanced B-cell and T-cell immunity. Brii Biosciences licensed BRII-179 (VBI-2601) from VBI Vaccines in December of 2018, providing Brii with commercial rights to BRII-179 (VBI-2601) in the licensed territories of China, Hong Kong, Macau, and Taiwan. Brii is developing the investigational candidate for the treatment of chronic hepatitis B virus (HBV) infection.
About Brii Biosciences
Brii Biosciences is a multi-national company committed to serving patients' needs and improving public health by accelerating the development and delivery of breakthrough medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight. With operations in the People's Republic of China and the United States, Brii Bio is poised to serve as a bridge to carry transformative medicines to patients, help create significant growth for our partners and establish an innovation engine to help improve the public health and wellbeing of patients around the world. Brii Bio is developing treatments for illnesses with significant public health burdens, including infectious diseases and CNS diseases. For more information, visit www.briibio.com.